n.abubakar98/100
Two lots ordered deliberately for comparison. Reported purities 0.1 points apart.
QST — Qingdao Saber Technology Pharmaceutical
Qingdao, CN · established 2017. The index holds 20 assay reports across 4 batches and 4 compounds, contributed by 6 laboratories. Every figure below is computed from those records and from nothing else.
Where QST sells
Qingdao Saber Technology Pharmaceutical sells from its own storefront. The link is marked nofollow and sponsored: it exists so the figures on this scorecard can be read against what the supplier itself publishes. The index is paid nothing for it and a link is not an assessment.
Visit QST at qingdaosabertechnology.com →
Every figure above describes lots the index has seen. It says nothing about the lot you are offered, and the only check that does is the one on the certificate against the vial.
Block 1
Identification
Business facts, held constant across the index and not derived from the data. The index sells nothing and takes no supplier payment for placement; the storefront link below is marked nofollow and sponsored so a record can be checked against the seller, and is not a recommendation.
- Legal name
- Qingdao Saber Technology Pharmaceutical
- Short code in this index
- QST
- Also known as
- QST · QST Biotech · Qingdao Saber Technology Pharmaceutical
- City
- Qingdao
- Region
- Qingdao
- Country
- CN
- Established
- 2017
- First record in index
- 19 Jul 2024
- Most recent record
- 27 May 2026
Block 1b
Dispatch and regional stock
Counted from the chain-of-custody line on this supplier's own records, which names the route each vial travelled to the laboratory, and from the on-record reviews below. The index has no sight of any supplier's warehouse network and publishes none.
Domestic-warehouse route
20.0%
n=20
Retail, shipped to the buyer
60.0%
n=20
Direct to the laboratory
20.0%
n=20
Median courier leg, direct despatch
9d
n=4
| Route to the laboratory | Records | Share |
|---|---|---|
| Domestic warehouse despatch | 4 | 20.0% |
| Retail purchase, shipped to the buyer | 9 | 45.0% |
| Retail purchase via a third-party forwarder | 3 | 15.0% |
| Supplier despatch direct to the laboratory | 4 | 20.0% |
Every record here carries a chain-of-custody line and that line names the route the vial travelled. Of the 20 QST records the index holds, 4 reached the contributing laboratory from a domestic warehouse rather than as a cross-border consignment, covering 2 of the 4 compounds QST is represented by here — NAD+, GHRP-6. Those are the QST lines this index has actually seen arrive from regional stock, and they are a count of consignments rather than a stock listing: a line missing from them may simply never have been submitted for assay.
No contributor to this index has named a regional stock location for QST. 4 of its records nevertheless arrived by a domestic-warehouse route, so stock is held somewhere; the index does not know where and will not guess.
The index measures nothing about lead time — it assays material, it does not buy it. What it has is QST's own reviewers: 6 of the 26 on-record reviews state a quoted window and what happened against it, and 1 of them describes same-day dispatch. Where QST despatched a sample direct to a laboratory, the courier leg ran a median 9 days across 4 such consignments — that is a transit time the index can see, and it is not the same thing as a lead time. The reviews are reproduced in full in Block 11.
Block 2
Headline statistics
Each figure carries the n it was computed from. The n= badge next to a statistic is the number of records it was computed from. Below n=8 the badge is amber. Below n=3 the statistic is suppressed and the individual values are shown instead.
Median purity
98.17%
n=20
Interquartile range
0.43pp
n=20
10th percentile
97.79%
n=20
Pass rate vs index spec
95.0%
n=20
Median recovery vs claim
97.8%
n=11
Median water
6.41%
n=20
Median |mass error|
3.3ppm
n=17
Records carrying a flag
15.0%
n=20
Block 3
Reproducibility across independent tests of one lot
Where the same physical lot was assayed more than once, the spread between those results is a property of the material and the fill, not of the market. It is the rarest and most informative statistic on this page, and it exists only for lots someone tested twice.
Median within-batch spread
suppressed
n=2
n<3 — see individual records
Index median spread
0.67pp
n=28
Lots tested 3+ times
2
n=4
Fewer than three QST lots have been assayed three or more times, so a reproducibility figure is not computed. Reproducibility cannot be inferred from the number of reports — it needs repeats on the same lot.
Block 4
Supplier certificate against independent measurement
The supplier's own COA purity figure for a lot, minus the median of the index's independent observations of the same physical lot. Positive means the certificate reads higher than the measurement. Rule AX-R05 fires above 1.5 pp.
Median COA divergence
+0.08pp
n=4
Index median divergence
+0.06pp
n=28
Divergences in the supplier's favour
50%
n=4
Divergences beyond 1 pp
0%
n=4
Block 5
Provenance — where the tested material came from
Supplier-supplied samples are weaker evidence than independently purchased ones, because the supplier chose the vial. The index measures the size of that effect rather than assuming it.
Buyer-sourced median
98.08%
n=16
Supplier-supplied median
98.74%
n=4
Supplier-supplied share of records
20.0%
n=20
Block 6
Documentation completeness
The score is not an opinion about paperwork. Each component is the share of QST batches in the index whose certificate carries that field, weighted as set out on the scoring rubric.
Documentation score
65/100
n=4
Index median score
85/100
n=28
| Certificate field | Batches carrying it | Rubric weight | |
|---|---|---|---|
| Purity figure stated | 100% | 25 points | |
| Analytical method stated (column, gradient, wavelength) | 75% | 25 points | |
| Peptide content stated | 0% | 20 points | |
| Endotoxin stated | 75% | 15 points | |
| Named impurities rather than a total | 15% | 15 points |
Block 7
Coverage by compound
The delta column is this supplier's median minus the index-wide median for the same compound, which is the only comparison worth making: comparing a supplier's aggregate against another supplier's aggregate compares their product mixes as much as their process control.
| Compound | Class | Reports | Median % | Index median % | Δ (pp) | Index spec | Pass % |
|---|---|---|---|---|---|---|---|
| Tirzepatide | Incretin | 11 | 98.40 | 98.55 | -0.15 | 97.0 | 100 |
| NAD+ | Non-peptide | 7 n=7 | 98.06 | 99.28 | -1.22 | 97.0 | 100 |
| MOTS-c | Metabolic | 1 n=1 | n<3 | 99.13 | — | 98.0 | 100 |
| GHRP-6 | Growth-hormone | 1 n=1 | n<3 | 99.54 | — | 99.0 | 0 |
Full per-compound breakdown with distributions and caveats →
Block 8
Quarterly trend
Submission volume is not market share and a quarterly median is not a trend unless the compound mix held still. Both caveats apply to every row below.
Median purity by quarter
Quarters with fewer than two purity records are gaps in the line rather than zeroes.
Coverage growth
Records added per quarter. Growth here is index coverage, not supplier volume.
Block 9
Which laboratory produced these numbers
Laboratories disagree with each other by a measured amount. A supplier tested mostly by one laboratory carries that laboratory's offset in its aggregate, and the adjusted column removes it.
| Laboratory | Reports | Median purity | Lab bias (pp) | Bias-adjusted |
|---|---|---|---|---|
| Janoshik | 9 | 98.17 | +0.00 | 98.17 |
| PeptideMeter | 3 | 97.61 | -0.05 | 97.66 |
| Medutest | 2 | n<3 | +0.08 | — |
| VendorInvestigate | 1 | n<3 | -0.11 | — |
| Nordanalyt | 3 | 98.40 | +0.02 | 98.38 |
| Kestrel | 2 | n<3 | +0.24 | — |
Bias figures are estimated from paired same-lot comparisons and are published with their confidence intervals on inter-lab agreement.
Block 10
What this data does and does not show
Block 11
On-the-record reviews 26
Reviews are signed statements from index contributors about their own testing of this supplier's material. They are opinions attached to evidence, and they are not used in any statistic on this page.
88.0/ 100363 ratings across the index network
h.moreau97/100
Labelling printed, lot and date legible on every unit examined. Figures as reported by the named service. Not reproduced by the index.
an.amankwah95/100
Purity by RP-HPLC, wavelength stated, stability-indicating method named. Determination is reproducible from the certificate alone. Quoted lead time from regional stock met to the day, and the price held for the quoted validity period.
l.haddad99/100
Line quoted that three comparable suppliers declined to quote. Material returned within specification. Documentation practice, not a single purity figure, is the substance here.
k.wojcik100/100
Phase-change pack solid on arrival and the cake intact. Cold chain held for the whole transit.
i.lindholm96/100
Direct-supply material 98.0%. Intermediary vial, same nominal description, 97.7%. Desiccant enclosed within the secondary container.
b.mwangi99/100
Cross-check: Janoshik and VendorInvestigate, same lot, agreement to 0.1 points. Both agree with the declared figure. Evidence base adequate for a rating on this criterion.
t.lindholm98/100
Supplementary certificate for a lot released 12 months earlier retrieved from supplier records on request.
w.sorensen96/100
Repeat determination at 8 months: 97.4%. Original: 97.4%. No drift detected in this sample. Submitted to the index in full.
v.abubakar95/100
Custom synthesis delivered 3 days inside the quoted schedule at the specified purity.
t.cardoso97/100
Packing: a cold pack that was still solid when the box was opened.
c.lindholm98/100
11 orders, 10 months. No substitution, no reformulation, no post-payment unavailability. Desiccant enclosed within the secondary container.
si.cabrera95/100
Retention time assigned to the principal peak, printed. Signature and release date present.
a.antonsen100/100
Quote correct at first issue and held to invoice. Documentation complete at first issue. Independent verification of individual lots still required.
h.beaulieu96/100
Transit 3 days from stock held in the United Kingdom against a quoted 3. Customs documentation correct at first presentation. Freight and documentation quoted separately from material cost, itemised on the invoice as quoted. Not medical advice.
s.correia100/100
Five orders, tracking live and accurate on each. No excipient. Cake intact.
j.lindholm99/100
Single lot identifier across the whole consignment. Intra-consignment comparison valid. Contributor declares no interest beyond the transaction.
k.varga95/100
Batch record supplied in full on request, attached rather than summarised.
c.danquah100/100
Labels printed square, lot code legible and matching the paperwork on every unit. Record covers the lots named. Not generalised.
f.frisk96/100
Consistency: 3 lots, purity band under 1.0 points wide. No further comment.
a.boateng99/100
Fill uniformity: 7 units weighed against declared fill, all within 2%. Per-milligram figure calculated against the certificate rather than against nominal fill, and it reconciled.
r.kimani98/100
Counter-ion identity and content answered quantitatively, one working day. No excipient. Cake intact.
e.almeida100/100
Quote correct at first issue and held to invoice. Declared and independent figures differ by less than repeatability. Submitted to the index in full.
d.radich96/100
Published stock status matched availability. Same-day dispatch.
ru.villalobos98/100
Lot QST-25-641 submitted to Janoshik. Declared 98.6%, reported 99.0%. Delta inside method repeatability. Signature and release date present.
k.okwuosa97/100
Documentation complete at first issue. No supplementary request raised. Peptide content 99.3%.
Block 12
Most recent records
Block 13
Contributor annotations on QST records 18
Annotations are this index's only discussion surface: signed technical comments attached to a specific record by a named contributor. They are not moderated for agreement with the index's own arithmetic. The most recent on QST material are below, each linked to the record it sits on.
Matrix occupancy on this compound is low. Every additional record moves the median visibly, which is the definition of a cell that should not be quoted.
Efficiency is the lever that does not change selectivity, so it improves resolution without moving anything else. Longer column, smaller particle, or lower flow, in that order of cost.
A reference standard on the same sequence would upgrade this from a good mass to a traceable one. The distinction matters where a result is going to be cited rather than merely read.
Deamidation is time, temperature and sequence. If the deamidated species is prominent here, the manufacture date on lot QST-2508-M5445 against the assay date above is the first arithmetic to do.
The actionable statistic for a buyer is not the median but the tenth percentile — how bad a bad lot is. This record is a data point for that percentile and it is worth more to the index than another result at the top.
Every named impurity on this record has a mass defect consistent with its structural assignment. That is the check that distinguishes an assignment from a guess.
Mass, retention and impurity profile all agree on this record. Three independent constraints pointing the same way is the strongest identity evidence the index publishes.
Research use does not require an endotoxin figure and most research use is not affected by one. The applications that are affected are affected badly.
Every annotation the index holds on QST material sits on its own record; the full set is reachable from the record listing and from each contributor's page. To read them against what QST itself publishes, open qingdaosabertechnology.com → alongside.
Block 14
Where to buy QST
Qingdao Saber Technology Pharmaceutical sells direct from qingdaosabertechnology.com. Everything on this page describes lots the index has already seen; the certificate that matters is the one that arrives with the vial you order, and the lot code on it should match the vial. Ask for the lot-specific document rather than the batch-level summary, and ask for the integration report if you intend to reconcile the figure yourself.
Go to the QST store at qingdaosabertechnology.com →
Marked nofollow and sponsored. The index is paid nothing for it, takes no commission, and a link is not an assessment. Research compounds. Not medical advice. Nothing on this site is a safety assessment and nothing on it is approved for human use.